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Abstract
Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder
that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early
in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia),
developmental delay, and autonomic symptoms.
In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders
(iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made
recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed
practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical
treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline
will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease.
Keywords: Aromatic l-amino acid decarboxylase deficiency, AADC deficiency, Neurotransmitter, Dopamine, Serotonin,
Guideline, Infantile dystonia-parkinsonism, SIGN, GRADE
German abstract
Der Aromatische L-Aminosäuren Decarboxylase Mangel (AADCD) ist eine seltene autosomal rezessive neurometabolische
Störung, die zu einem schweren kombinierten Mangel an Serotonin, Dopamin, Norepinephrin und Epinephrin führt. Die
Symptome setzen in einer frühen Phase des Lebens ein. Die klinischen Hauptsymptome sind muskuläre Hypotonie,
Bewegungsstörungen (Okkulogyre Krisen, Dystonie und Hypokinesie), Entwicklungsverzögerung und autonome
Symptome.
In diesen Konsensus basierten Leitlinien haben Mitglieder der “International Working Group on Neurotransmitter Related
Disorders (iNTD)” sowie Patientenvertreter die verfügbare Evidenz für die Diagnose und Behandlung von AADCD
ausgewertet und evidenzbasierte Empfehlungen nach den Methoden von SIGN und GRADE formuliert. Stets im
Bewusstsein der limitierten Evidenz haben wir praktische Empfehlungen für die klinische Diagnose, Labordiagnose,
Bildgebung und EEG, medizinische und nicht medizinische Behandlung formuliert. Des Weiteren haben wir Themen
identifiziert, die der weiteren Forschung bedürfen. Wir glauben, dass diese Leitlinie die Behandlung von Patienten mit
AADCD verbessert und gleichzeitig das Bewusstsein für diese seltene Erkrankung geschärft wird.
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Spanish abstract
La deficiencia de la descarboxilasa de aminoácidos aromáticos (AADCD) es una enfermedad neurometabólica
minoritaria de herencia autosómica recesiva que causa un defecto grave de dopamina, serotonina, epinefrina y
norepinefrina. El inicio de la enfermedad es precoz, y sus síntomas principales incluyen hipotonía, trastornos del
movimiento (crisis oculógiras, distonía e hipocinesia), retraso del desarrollo y signos disautonómicos.
En esta guía de consenso han participado representantes del grupo de trabajo internacional sobre trastornos de la
neurotransmisión (iNTD) y representantes de las asociaciones de pacientes, que han evaluado todas las evidencias
existentes en relación al diagnóstico y tratamiento de la AADCD. Las recomnedaciones se han realizado siguiendo
la metodología SIGN y GRADE. A pesar de los bajos niveles de evidencia existentes, se han podido establecer
recomendaciones prácticas y que pueden ser muy útiles sobre el diagnóstico clínico y de laboratorio, las pruebas
de neuroimagen y electroencefalográficas y sobre tratamientos tanto médicos como de soporte. Se han
identificado además temas que pueden ser interesantes a desarrollar en el campo de la investigación de la AADCD.
En conclusión, pensamos que esta guía aumentará la calidad en los cuidados de los pacientes con AADCD en todo
el mundo, y que aumentará el conocimiento de esta rara enfermedad.
Background
Aromatic L-amino acid decarboxylase (AADC; EC
4.1.1.28) is the final enzyme in the biosynthesis of the
monoamine neurotransmitters serotonin and dopamine,
and dopamine is the precursor for norepinephrine and
epinephrine. AADC deficiency (AADCD; OMIM
608643) is a rare, autosomal recessive neurometabolic
disorder that leads to a severe combined deficiency of
serotonin, dopamine, norepinephrine and epinephrine
(Fig. 1) [1]. About 100 patients have been described in
case reports or case series since the initial description of
the index family in 1990 [2, 3]. The global incidence of
AADCD is unknown, and there are no newborn screen-
ing programs, but it is more prevalent in certain Asian
(especially Taiwanese and Japanese) populations, prob-
ably due to a founder effect [4]. Symptom onset typically
occurs during the first months of life [2]. While most pa-
tients present a severe phenotype with early onset hypo-
tonia, oculogyric crises, ptosis, dystonia, hypokinesia,
impaired development and autonomic dysfunction [2], a
few patients with a milder disease course are known [5].
Due to the rarity of AADCD, there is limited inter-
national clinical expertise for evidence-based manage-
ment. Treatment response is often disappointing and
treatment strategies vary between single expert centers
[6]. Some patients are treated with a variety of different
drugs, while others only receive one or two different
drug classes [2]. A small subset of patients shows a good
response to L-Dopa [7] or dopamine agonists [5], but
often patients show no or poor response [2]. For most
patients, treatment response cannot be predicted.
To improve care for patients with neurotransmitter
related disorders, including AADCD, the International
Working Group on Neurotransmitter Related Disor-
ders (iNTD) was founded in 2013 [8]. Today, iNTD
is a growing worldwide network of 38 neurometabolic
centers from 24 countries. In addition to keeping a
patient registry [9], one of its goals is to develop con-
sensus care guidelines for neurotransmitter related
disorders by pooling all published evidence and ex-
perience of leading expert centers. This guideline on
diagnosis and treatment of AADCD is the first guide-
line developed by iNTD.
In this guideline, developed with the Scottish Intercol-
legiate Guideline Network (SIGN) methodology, we
present the key clinical symptoms and the recommended
strategy for diagnosis and management of AADCD
based on a systematic review of the literature and con-
sensus meetings of the iNTD guideline working group.
The guideline is intended for metabolic specialists, child
and adult neurologists, pediatricians, intensive care spe-
cialists, nurses, and paramedical specialists involved in
the care of patients with AADCD.
Methods
Composition of the guideline working group and timeline
An executive committee (TO (chairman), TW (secre-
tary), MM and KJ) was appointed to oversee the guide-
line development process and to function as
coordinators for the subgroups focusing on different
topics. The guideline working group consisted of 13
child neurologists (TW, GH, BA, AC, MK, WL, RP, TP,
VL, MMa, PP, MW, TO), 5 biochemists (MM, NB, RA,
SH, MV), and 1 research project manager (KJ) from sev-
eral European countries, the USA and Taiwan. All group
members are affiliated to iNTD and are experienced in
the diagnosis and treatment of AADCD. Furthermore, a
representative of the European AADCD patient
organization (LF, AADC Research Trust) participated in
guideline development. Finally, according to SIGN
guidelines, two external academic reviewers with expert-
ise in neurometabolic and movement disorders (Ron
Wevers, Nijmegen, the Netherlands and Russell Dale,
Sydney, Australia), and one additional lay reviewer were
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asked to comment on the draft before submission.
The final version of the guideline was pilot-tested for
use in clinical practice by non-specialist neurologists
in training. A preliminary guideline working group
meeting took place in November 2014 (London, UK)
during the AADC Research Trust Conference. The
start-up meeting took place in Barcelona, Spain (Feb-
ruary 2015). Further face-to-face meetings were held
in Heidelberg, Germany (September 2015, executive
committee only), in Venice, Italy (November 2015),
and a final wrap-up meeting was held during the
AADC Research Trust Conference in May 2016
(London, UK).
Developing topics and key questions
During the start-up meeting, the initial list of key ques-
tions compiled by TW and TO was discussed and re-
fined. The group was divided in subgroups focusing on
the following topics: (I) Clinical Presentation; (IIa) Diag-
nosis: laboratory tests; (IIb) Diagnosis: imaging; (III)
Treatment; (IV) Complications and Long-Term Manage-
ment; (V) Social Issues and Transition; and (VI) Special
Fig. 1 Biosynthesis and breakdown of serotonin and the catecholamines, and the metabolic block in AADC deficiency. Simplified scheme of the
biosynthesis and breakdown of serotonin and the catecholamines (dopamine, norepinephrine and epinephrine), and melatonin synthesis. Cofactors
(BH4, PLP, Cu) and methyldonor (SAM) are connected to the respective enzyme with dashed lines. Dashed arrows do not show intermediate steps.
The metabolic block caused by AADC deficiency is shown as a red bar. Metabolites above the block are increased, metabolites below the block are
decreased, indicated by red arrows. The implication of 5-MTHF in L-dopa to 3-OMD metabolism is shown in a simplified manner. Norepinephrine and
epinephrine are broken down to NMET and MET only in the periphery. In CSF, the main metabolite of norepinephrine and epinephrine is MHPG.
Abbreviations: AADC: aromatic l-amino acid decarboxylase; BH4: tetrahydrobiopterin; COMT: catechol O-methyl transferase; CSF: cerebrospinal fluid; Cu:
cupper; DβH: dopamine beta hydroxylase; DOPAC: dihydroxyphenylacetic acid; HCys: homocysteine; 5-HIAA: 5-hydroxyindoleacetic acid; 5-HTP: 5-
hydroxytryptophan; HVA: homovanillic acid; L-Dopa: 3,4-dihydroxyphenylalanine; MAO: monoamine oxidase; MET: metanephrine; Met: metionine; MHPG:
3-methoxy 4-hydroxyphenylglycol; 3MT: 3-Metyramine; 5-MTHF: methyltetrahydrofolate; NMET: normetanephrine; 3-OMD: 3-O-methyldopa
(=3-methoxytyrosine); Phe: phenylalanine; PhH: phenylalanine hydroxylase; PNMT: phenylethanolamine N-methyltransferase; SAH: S-adenosylhomocysteine;
SAM: s-adenosylmethionine; TH: tyrosine hydroxylase; TrH: tryptophan hydroxylase; Tryp: tryptophan; Tyr: tyrosine; VLA: vanillactic acid; VMA: vanillmandelic
acid: Vit B6 vitamin B6 (pyridoxine)
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Situations. See Additional file 1: Table S1 for the final
list of key questions.
Systematic literature search
A systematic literature review on AADCD was per-
formed through December 2015 on Pubmed, Cochrane
database, and the Cinahl database, using “aromatic (l)
amino acid decarboxylase deficiency” and “AADC defi-
ciency” as search terms. No language or data filters were
used. The literature database on the official website of
the AADC research trust was searched for applicable ar-
ticles [10]. The reference list of the large case series of
Brun [2] was screened for additional sources. Further-
more, reviews on monoamine neurotransmitter deficien-
cies were searched using Pubmed, search term
“monoamine neurotransmitter disorders’, limits: review,
English, from 1990. The WHO registry for clinical trials
[11] and the NIH registry for clinical trials [12] were
searched. Finally, reference lists from review articles and
key case series were screened for additional hits and
members of the guideline group were asked to suggest
relevant book chapters. Because of the limited number
of publications on AADCD, conference abstracts from
posters or symposia were included for literature review,
but only if they were not followed by a peer reviewed
publication from the group. The flow chart with results
of the literature search can be found as Additional file 2:
Figure S1.
Grading of evidence and recommendations
The guideline was developed according to SIGN [13].
For rating the quality of evidence and defining strength
of recommendations, SIGN is committed to using the
GRADE methodology [14–17]. Level of evidence of indi-
vidual studies was rated in a range from 4 (lowest) to 1+
+ (highest) (Table 1). Specific outcomes (e.g. effect of a
specific drug on hypotonia) were described with a cer-
tain level of evidence (very low, low, moderate or high)
for the total body of evidence. Recommendations were
rated as strong (for or against), conditional (for or
against), or recommendation for further research
(Table 2). Furthermore, Good Practice Points (GPP)
were formulated based on the clinical experience of the
guideline development group. Relevant papers were eval-
uated by at least two guideline working group members.
Before and during meetings, the guideline group mem-
bers were trained on standardized literature evaluation
using SIGN/ GRADE methodologies. All recommenda-
tions were discussed for consensus during guideline
group meetings.
Disclaimer
The purpose of this guideline is to improve care for pa-
tients with AADCD and is based on the best available
evidence. However, AADCD being a very rare disorder,
the body of evidence encompasses mainly non-analytical
studies and case reports. Therefore, many recommenda-
tions reflect expert opinion. This guideline is meant to
give a solid foundation to caregivers who look after
AADCD patients, but should never replace sensible,
well-informed clinical care.
Part I: Clinical presentation
Number of reports; literature search
In addition to the 78 patients reported in the large case
series of Brun et al in 2010 [2], 39 individual patients
were identified in a total of 13 reports [3, 5, 18–28]. A
further 22 cases, partly described in conference ab-
stracts, could not with certainty be distinguished as indi-
vidual patients [24, 29–33]. In other words, 117 to 139
AADCD patients have been described so far, and 117 pa-
tients were used for calculations of patient characteris-
tics. The comprehensiveness of the clinical information
and the amount of biochemical and molecular data
available differed substantially between included reports.
Six families with multiple affected members were de-
scribed [1, 7, 34–37]. Of the 117 patients clearly identi-
fied as individual AADCD cases, 56 were male, 42 were
female, and in 19 gender was not reported.
Ethnic origin
Many reported patients (50/117) are Asian. It is known
that there is an increased prevalence of AADCD in pa-
tients from southern Chinese descent, especially from
Taiwan and Japan, due to the founder variant IVS6 +
4A > T [4]. Other reported ethnic origins are: Caucasian
(n = 33), Arabic (n = 4), Iranian (n = 1) and Jewish (n =
2). Ethnic origin was not described or remained uncer-
tain in 21 cases.
Table 1 Levels of evidence according to SIGN
Levels of evidence
1+
+
High quality meta-analyses, systematic reviews of RCTs or RCTs
with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a
low risk of bias
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2+
+
High quality systematic reviews of case control or cohort studies
High quality case control or cohort studies with a very low risk of
confounding or bias and a high probability that the relationship is
causal
2+ Well conducted case control or cohort studies with a low risk of
confounding bias and a moderate probability that the relationship
is causal
2- Case control or cohort studies with a high risk of confounding or
bias and a significant risk that the relationship is not causal
3 Non-analytic studies, e.g. case reports, case series
4 Expert opinion
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R#1 (strong): There should be an increased level of
awareness for AADCD in patients of Chinese/Taiwan-
ese/Japanese descent, because of the presence of a
founder variant (IVS6 + 4A > T).
Age of onset and age of diagnosis
The age of onset of signs and symptoms, clearly docu-
mented in 68 cases only, was within the first year of life
(mean: 2.7 months, SD ± 2.7). Eleven patients presented
in the neonatal period with hypotonia, or floppiness.
Based on available data (mostly level 3, with non-
standardized methods of reporting symptoms), it was
not possible to describe the precise age of onset and
duration of every symptom associated with AADCD.
Table 3 summarizes the best available data from pub-
lished cases regarding the onset of symptoms. Despite
the early onset of symptoms, mean age of diagnosis was
3.5 years (median 13 months, range 2 months – 23 years,
26 % missing data).
Key symptoms and signs
Key symptoms of AADCD are: hypotonia (present in n
= 91 patients, absent in n = 3 patients, not mentioned in
n = 23 patients), movement disorders (present n = 99, ab-
sent n = 3, not mentioned n = 15), developmental delay
(present n = 84, absent in n = 1 only [18], not mentioned
n = 32), and autonomic symptoms (present n = 76, ab-
sent n = 3, not mentioned n = 38). All key symptoms
ranged in severity from mild to very severe. Hypotonia is
most often axial, and sometimes accompanied by limb
hypertonia. Movement disorders most often described
are oculogyric crises (n = 91), dystonia (n = 63), and
hypokinesia (n = 40). Most prominent autonomic signs
are ptosis, excessive sweating, and nasal congestion.
Hypotension or orthostatic hypotension was reported in
15 patients, with onset mostly in late childhood or ado-
lescence. In 14 patients, blood pressure was reported to
be normal. A complete list of movement disorders, auto-
nomic symptoms and signs, and other clinical character-
istics is given in Table 3.
R#2(strong): In children with unexplained hypotonia,
movement disorders (especially oculogyric crisis),
developmental delay, and autonomic symptoms,
AADCD should be considered.
Other neurological findings
Epileptic seizures were described in 9 patients [2, 7, 22,
38–40]. Behavioral problems can be a great burden to
patients and caregivers but are not well defined in the
literature. They were reported to be present in 41 cases,
mostly described as irritability, excessive crying, dys-
phoria [2, 40, 41] and autistic features [31]. Sleep dis-
turbance (both insomnia and hypersomnia) was
described in 34 patients. Some patients may suffer from
severe sleep apnea, which may be lethal (personal obser-
vation WL). In some patients, diurnal fluctuations and
improvement after sleep, a classical finding for many
neurotransmitter disorders [6], is reported. On neuro-
logical examination, deep tendon reflexes can be de-
creased, normal or increased. Pathological reflexes
including Babinski sign are sometimes reported.
R#3 (research): Behavioral symptoms and sleep dis-
turbances in AADCD should be better defined, to im-
prove patient care.
Additional clinical findings
Gastrointestinal problems can be prominent in AADCD.
Symptoms can include diarrhea, constipation, gastro-
esophageal reflux, and feeding difficulties. Many patients
receive and benefit from a gastrostomy (expert experi-
ence). Failure to thrive and short stature is often re-
ported. In 13 patients, intermittent hypoglycemia was
reported, at birth or in the first five years of life.
Hypoglycemia can occur during intercurrent illnesses
[41]. In one patient, hypoglycemia with reduced level of
consciousness was found after sedation for MRI [42].
There are no reports of growth hormone deficiency, thy-
roid deficiency, or other hormone deficiencies in
AADCD.
Phenotypic spectrum and clinical course
Based on clinical description, cases were broadly classi-
fied as mild (mild delay in developmental milestones,
ambulatory without assistance, mild intellectual
Table 2 Forms of recommendations according to GRADE
Judgment Recommendation
Undesirable consequences clearly outweigh desirable consequences Strong recommendation against
Undesirable consequences probably outweigh desirable
consequences
Conditional recommendation against
Balance between desirable and undesirable consequences is closely
balanced or uncertain
Recommendation for research and possibly conditional recommendation for
use restricted to trials
Desirable consequences probably outweigh undesirable
consequences
Conditional recommendation for
Desirable consequences clearly outweigh undesirable consequences Strong recommendation for
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Table 3 Symptoms and signs described in AADC deficiency
Symptom/ sign Neo natal Infancy Child hood Adolescence Adulthood
CNS Tone regulation Floppy infant + ++
Hypotonia (mainly truncal) + ++ ++ ++ ++
Poor head control + + + + +
Hypertonia (mainly limbs) + + + + +
Movement disorders Dyskinesia (eg hyperkinesia, chorea, athetosis) ± + + + +
Dystonia - ++ ++ ++ ++
Oculogyric crisis ± ++ ++ ++ ++
Hypokinesia and/ or bradykinesia ± ++ ++ ++ ++
Myoclonus ± ± ± ± ±
Tremor ± ± ± ± ±
Developmental Delay Delayed motor development ± ++ ++ ++ ++
Delayed cognitive development ± + + +
Delayed speech development ± + + +
Behavioural Problems Irritability ++ ++ + + +
Autistic features ± ± ±
Dysphoria/ Mood problems ± ± ± ± ±
Excessive crying + ++ + - -
Sleeping Problems Insomnia and or hypersomnia + + + +
Other Epileptic seizures - ± ± ± ±
Fatiguability ± ± ± ± ±
Diurnal fluctuation ± ± ± ±
Dysarthria ± ± ±
Poor eye fixation + + + +
Increased startle ± ± ± ± ±
ANS Eyes Ptosis + + + + +
Miosis ± ± ± ± ±
Upper respiratory tract Nasal congestion - + + ± ±
Excessive drooling - + + ± ±
Stridor ± ± ± ± ±
Skin Excessive sweating - + + + +
Homeostasis Temperature instability + + + + +
Cardiovascular (Orthostatic) Hypotension - - ± + +
Bradycardia ± ± ± ± ±
Heart rhytm abnormalities ± ± ± ±
Gastrointestinal Diarrhea ± + + + ±
Obstipation ± + + + ±
Metabolic/ endocrine Hypoglycemia ± ± ± - -
Hyperprolactinemia ± ± ± ± ±
General Feeding/ Swallowing Problems + + + + +
Gastrointestinal reflux + + + ± ±
Gastrointestinal problems unspecified + ++ + + +
Failure to thrive ± + + +
Contractures - - - ± ±
Small hand and feet ± ± ± ± ±
Best available evidence for all published clinical symptoms and the age of occurrence (additional literature used: [77]). CNS Central Nervous System. ANS
autonomic nervous system. ++ very often (key symptom); + often; ± sometimes; - not expected
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disability), severe (no or very limited developmental
milestones, fully dependent), and moderate (in between).
Six cases could be classified as mild (reported in [5, 18,
19, 35, 43]), 15 as moderate (reported in [2, 5, 7, 20, 22,
31, 35, 40, 44, 45]), and 82 as severe. For 14 cases, insuf-
ficient information about the clinical picture was avail-
able. Importantly, a mild phenotype can present
predominantly with autonomic symptoms (diarrhea, epi-
sodic hypoglycemia, nasal congestion) and without evi-
dent movement disorders [18]. Two adult sisters had a
very atypical clinical course, with hypotonia at birth,
moderate to severe motor developmental delay in in-
fancy, and mild to moderate symptoms in childhood,
with improvement during puberty [5]. The two other pa-
tients who were diagnosed as adults did not show transi-
ent improvement in puberty, but rather a deteriorating
clinical picture [7]. Deterioration with loss of skills, e.g.
regression of language skills [20, 22], is described in
some patients but in the majority of cases, there is no
evident progressive clinical course with loss of function
described. A decline in motor function can sometimes
be due to secondary factors like joint contractures [46].
R#4 (conditional): The phenotypic spectrum of
AADCD is broad and can range from very severe to
relatively mild. AADCD should also be considered in pa-
tients with autonomic symptoms without obvious move-
ment disorders.
R#5 (strong): A deteriorating clinical course is not ex-
pected in patients with AADCD and should trigger a
diagnostic work-up for other diseases.
Phenotype correlations with genotype or biochemical
phenotype
There are >50 different DDC gene disease causing vari-
ants described in AADCD but clear genotype/ pheno-
type correlations could not be established. However,
patients with the founder splice variant IVS6 + 4A > T
(36 patients in total, 26 with homozygous variants) all
had a severe phenotype without reaching clear develop-
mental milestones, except for two sisters with the com-
pound heterozygous variants p.[R285W];[IVS6 + 4A > T]
and a mild to moderate clinical picture with response to
treatment [35]. The variant p.[R285W],c.[853C > T] is
not reported in other patients. Gender is not associated
with phenotype (severe phenotype in 72 % of females
and 77 % of males).
There is evidence for a genotype/ treatment response
correlation in two families with different L-Dopa binding
site variants and a convincing response to L-Dopa.
Three siblings, extensively represented in the literature,
with a homozygous p.[G102S], c.[304G > A] variant be-
came able to walk independently (n = 1) or with assist-
ance (n = 2) and showed improvement of dystonia,
truncal hypotonia and speech after L-Dopa treatment
was started [7, 40, 47]. More recently, a patient with
other variants affecting the L-Dopa binding site
p.[R347Q];[R160W], c.[1040G > A];[478C > T], also
showed a good response to L-Dopa [19]. Currently,
therapeutic implications of other DDC gene variants in
AADCD are being investigated [48].
There is overlap in cerebrospinal fluid (CSF) values of
biogenic amines in mild, moderate and severe cases
without a clear correlation of the biochemical (CSF) and
clinical phenotype. Plasma AADC enzyme activity does
not correlate with clinical phenotype; in both mild and
severe cases it can be below the detection limit of the
assay.
R#6 (conditional): There are no clear genotype/ bio-
chemical or clinical phenotype correlations in AADCD
except for the homozygous IVS6 + 4A > T splice variant
that is associated with a severe phenotype in all cases re-
ported to date, and rare L-Dopa binding site variants
that are associated with L-Dopa responsiveness.
Part IIa: Diagnosis: laboratory tests
Key diagnostic tests: CSF, AADC activity and genetic
testing
Lumbar puncture
The typical CSF pattern in AADCD consists of (1) low
levels of 5-hydroxyindoleacetic acid (5-HIAA), homova-
nillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol
(MHPG), (2) normal pterins including neopterin and
biopterin, and (3) high concentrations of 3-O-
methyldopa (3-OMD), L-Dopa and 5-OH tryptophan (5-
HTP). This reflects the metabolic block at the level of
AADC (Fig. 1). Low HVA and 5-HIAA was reported in
99 % of patients. Only two sisters with a mild phenotype
had normal HVA (124 and 169 nmol/L; ref 98-
450 nmol/L), one of them also had normal 5-HIAA
(50 nmol/L; ref 45-135 nmol/L). In both patients, 3-
OMD and -5-HTP were increased and MHPG was de-
creased [5]. In only one patient, normal MHPG was re-
ported, with decreased HVA and 5-HIAA [19]. Normal
CSF pterins (neopterin, dihydrobiopterin and tetrahydro-
biopterin) are essential to differentiate AADCD from the
tetrahydrobiopterin disorders [6].
The CSF profile of AADCD may be similar to the pro-
file found in pyridox(am)ine 5-phosphate (PNPO) defi-
ciency, in which there is a secondary failure of AADC
due to a deficiency of its cofactor pyridoxal phosphate
(PLP). However, additional findings in this disorder are
very low PLP, and increased glycine and threonine in
CSF. Furthermore, the clinical picture of PNPO defi-
ciency, namely a severe neonatal epileptic encephalop-
athy, is different from the clinical presentation of
AADCD [49, 50].
Mildly decreased CSF 5-methyltetrahydrofolate (5-
MTHF) was reported in only 1 patient with AADCD
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[47], and 5-MTHF levels decreased during L-Dopa treat-
ment in 3 patients [40]. It was proposed that this could
be due to a depletion of CSF s-adenosylmethionine
(SAM) in states with increased L-Dopa concentrations
[51], but serial CSF measurements for 5-MTHF have not
been performed in other patients.
Neurotransmitter metabolite analysis is performed in a
limited number of specialized laboratories. For an online
list of iNTD affiliated laboratories, see [8]. Collection
and handling of CSF should be performed strictly fol-
lowing standardized procedures to ensure correct inter-
pretation of results. For a review see Hyland [52].
R#7 (strong): AADCD can be diagnosed in CSF. Spe-
cific measurements in CSF should include the core me-
tabolites HVA, 5-HIAA, 3-OMD, L-Dopa, and 5-HTP,
and pterins. If available, 5-MTHF and PLP should also
be measured. Reduced 5-HIAA and HVA, and elevated
3-OMD, L-Dopa and 5-HTP, with normal pterins, point
to AADCD.
R#8 (GPP): CSF measurements should always include
standard measurements (cells, protein, glucose, lactate).
Collection and handling of CSF should be performed
strictly following standardized procedures to ensure cor-
rect interpretation of results.
AADC activity in plasma
Enzyme assays measuring AADC activity in plasma can
be performed using both L-Dopa and 5-HTP as sub-
strate. Since L-Dopa gives a higher analytical yield it is
used as the standard method. All 57 papers that reported
results of plasma AADC activity assays, described de-
creased activity in patients with AADCD. In about 30 %
of reported cases, AADC activity was below detection
limits. The highest reported residual enzyme activity in
AADCD was 12 pmol/mL/min (33 % of the lower limit
of normal), reported in 1 patient [41]. AADC activity is
also decreased in heterozygous carriers (35-40 % of nor-
mal) [18, 34, 35, 53]. For an online list of iNTD affiliated
laboratories that perform AADC activity assays, see [8]
R#9 (strong): AADCD can be diagnosed by demon-
strating severely decreased AADC activity in plasma.
Plasma AADC activity is moderately reduced in hetero-
zygous carriers.
Molecular diagnosis
About 50 disease causing DDC variants have been de-
scribed so far: 39 substitution variants, 2 nonsense, 5 de-
letions, 1 insertion and 4 splice variants. For an up to
date list of DDC variants, see online locus-specific data-
base on PNDdb [54]. In only two AADCD patients with
the classical CSF profile and decreased AADC activity in
plasma, no variants of the DDC gene were found despite
Sanger analysis of the coding region, the exon/intron
boundaries and flanking untranslated regions [39, 41]. In
two other patients (siblings),with the classical CSF pro-
files and very low plasma AADC enzyme activity, only
one variant was detected [36]. It is assumed that in these
cases a second variant may be intronic, within the pro-
moter region or a heterozygous deletion or duplication,
undetectable by current standard diagnostic techniques.
Two recent reports detected AADCD patients using
whole exome sequencing [20, 55].
R#10 (strong): In the great majority of patients,
AADCD can be genetically confirmed.
Concluding statements regarding key diagnostic tests
R#11 (strong): There are three core diagnostic keys for
identifying AADCD:
(1)low CSF levels of 5-HIAA, HVA, and MHPG, in-
creased CSF levels of 3-OMD, L-Dopa and 5-HTP,
and normal CSF pterins
(2)compound heterozygous or homozygous pathogenic
variants in the DDC gene
(3)decreased AADC enzyme activity in plasma
To diagnose AADCD, genetic testing should be per-
formed and at least two out of three core diagnostic
tests should be positive.
R#12 (strong): If genetic diagnosis is performed as the
first step (e.g. whole exome sequencing or affected fam-
ily member), functional confirmation should be com-
pleted by measuring AADC enzyme activity in plasma
and/or neurotransmitter metabolites in CSF.
R#13 (conditional): If local resources allow, we rec-
ommend performing all three key diagnostic tests in pa-
tients with this rare disorder.
R#14 (GPP): The results of CSF analysis and plasma
AADC activity measurement are generally available be-
fore results of genetic testing. Genetic confirmation
should not be awaited before initiating therapy.
Other diagnostic tests in AADCD
Prolactin
Prolactin in blood can be increased in dopamine biosyn-
thesis disorders, because dopamine serves as an inhibitor
of prolactin secretion [6]. Prolactin was reported in 13
AADCD patients. Elevated prolactin was found in 6 pa-
tients; in the others it was normal. Also, members of the
guideline group reported normal prolactin in multiple
AADCD patients (non-published observations).
R#15 (research): Normal prolactin level in blood does
not exclude AADCD. To better understand this mech-
anism we recommend further research on this topic.
Neurotransmitter (metabolites) in blood
Whole blood serotonin was reported in 15 patients and
found to be decreased in all of them [1, 34, 39, 40, 56].
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Plasma monoamine and monoamine metabolites (L-
Dopa, 3-OMD, vanillactic acid (VLA), HVA, vanillyl-
mandelic acid (VMA), MHPG, norepinephrine, epineph-
rine, and 5-HTP) are reported in a very limited number
of patients and it is not possible to draw conclusions
about the diagnostic accuracy of these tests. Plasma
measurements cannot replace measurements in CSF.
R#16 (strong): Measurement of catecholamine metab-
olites in blood are not useful in routine clinical practice,
because it neither diagnoses nor excludes AADCD.
Dried blood spot measurement of 3-OMD
One report studied the use of dried blood spot (DBS)
testing of 3-OMD in 15 patients [57]. All samples
showed an at least 15-fold increase of 3-OMD. In 6 pa-
tients, newborn values were available, showing very high
levels of 3-OMD. However, 3-OMD is also increased in
PNPO deficiency. There are no other reports on this
subject available. If (newborn) screening can reliably
diagnose AADCD, this will greatly improve the diagnos-
tic delay that is often encountered now. A clinical trial
on newborn screening of AADCD is currently recruiting
patients in Taiwan [12].
R#17 (research): The development, diagnostic accur-
acy, and cost effectiveness of DBS analysis of 3-OMD for
(newborn) screening for AADCD should be further
investigated.
Urine measurements of neurotransmitter metabolites
Increased urine vanillactic acid (VLA) levels, measured
by organic acid analysis, are reported in AADCD. How-
ever, this elevation is often subtle and easily missed if
not specifically looked for in a specialised laboratory [2].
Dopamine, HVA and vanilylmandelic acid (VMA) in
urine are not reliable as biomarkers in AADCD because
they can either be normal, decreased or increased [2, 26,
58]. This is due to very high AADC activity within the
kidneys, accounting for sufficient residual AADC activity
to form dopamine and its metabolites [27].
R#18 (conditional): If urinary VLA is increased,
AADCD should be considered. However, normal levels
do not exclude the diagnosis.
R#19 (strong): Measurement of catecholamine metab-
olites in urine is not useful as a diagnostic test in clinical
practice, because it can neither diagnose nor exclude
AADCD.
Other diagnostic tests
Melatonin is formed from serotonin and would be ex-
pected to be decreased in AADCD. Theoretically, it is
therefore a possible diagnostic tool for this patient
group, but no reports on melatonin measurements are
available. One recent report used global metabolomics
assisted pathway screening with plasma samples in one
AADCD patient, and showed an increased 3-OMD. This
finding was also seen in subjects using L-Dopa/ carbi-
dopa medication [55].
R#20 (research): Other diagnostic tests that might in-
crease knowledge on AADCD and/ or serve as possible
biomarkers are melatonin and broad metabolomic
screening for specific AADCD related markers.
Part IIb: Diagnosis: imaging and
electroencephalography
Magnetic resonance imaging (MRI) of the brain
Brain imaging was performed in 38 cases (36 MRI, 2
CT), and was described as normal in 25. In the
remaining cases, described abnormalities were heteroge-
neous, including: diffuse mild cerebral atrophy [2, 38],
cortical atrophy [41], reduced prefrontal volume with
normal myelination and normal basal ganglia [36], focal
demyelination changes over bilateral frontal and left par-
ietal area [4], leukomalacia [4], degenerative changes of
white matter, thinning of corpus callosum, prominent
ventricular bodies, leukodystrophy-like patterns, and
hypomyelination [2]. Since there is no specific MRI pat-
tern, imaging is not helpful in the diagnosis of AADCD.
However, it is usually necessary in the work-up of a pa-
tient with neurodevelopmental delay to exclude other
conditions in the differential diagnosis. Following stan-
dards of good clinical care, neuroimaging is always indi-
cated if there is an unexpected deviation of clinical
course in a diagnosed AADCD patient (see also R #5).
R#21 (conditional): Routine imaging of the brain is
not needed to diagnose AADCD.
R#22 (GPP): In the work-up of patients with neurode-
velopmental delay, and in unexpected deviation of clin-
ical course in AADCD patients, brain imaging should be
considered.
Electroencephalography (EEG)
EEG, reported in 28 cases, was described as normal in 21.
In the remaining cases described abnormalities included:
epileptiform abnormalities in a patient with clinical sei-
zures [38], epileptiform abnormalities (paroxysmal dis-
charges, (multifocal) sharp waves, polyspikes) without
evident clinical seizures in three patients [2, 56, 59], un-
specific changes [41], and rapid activity or slowing [2].
EEG is not needed to diagnose AADCD. However, if there
is a clinical suspicion of epilepsy, to differentiate oculogy-
ric crises from epileptic events [7], or in the general work-
up of neurodevelopmental delay, EEG can be performed
following local standards of good clinical care.
R#23 (conditional): EEG is not needed to diagnose
AADCD.
R#24 (GPP): EEG can be used in the work-up of
AADCD if there is a clinical suspicion of epilepsy, to
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differentiate oculogyric crises from epileptic events, or in
the general work-up of neurodevelopmental delay.
Other imaging modalities
A brain fluorodeoxyglucose (18F-FDG) PET scan was
performed in only 1 patient [36], and demonstrated re-
duced uptake in the prefrontal cortex and bilateral basal
ganglia. Striatal uptake of fluorodopa (FDOPA) on PET/
CT was reported to be very low at baseline, and in-
creased after gene therapy in 3 patients [24]. There were
no published reports of DAT scans in AADCD.
R#25 (research): Other imaging modalities (FDG PET,
FDOPA PET, DAT-scan) have no role in routine clinical
care but can be useful in research settings, e.g. the as-
sessment of the efficacy of gene therapy.
Part III: Treatment
IIIa: Medical treatment
Available evidence
Based on the literature evaluation, considered judgments
leading to recommendations for use in clinical practice
could be constructed for dopamine agonists, monoamine
oxidase (MAO) inhibitors, pyridoxal phosphate, pyridox-
ine, anticholinergic agents, folinic acid, L-Dopa with carbi-
dopa, L-Dopa without carbidopa, 5-hydroxytryptophan,
benzodiazepines, melatonin, and selective serotonin re-
uptake inhibitors (SSRIs). For catechol O-methyl transfer-
ase (COMT)-inhibitors there was insufficient literature
available to come to a recommendation. The quality of
the total body of evidence for specific outcomes was rated
as low or very low. There are currently no active medical
treatment trials in AADCD registered.
First line treatment
Dopamine agonists
Dopamine agonists activate postsynaptic dopamine re-
ceptors directly. Ergot-derived dopamine agonists with
strong serotonergic (5HT2b) agonist action (pergolide
and cabergoline) are strongly associated with cardiac val-
vulopathy and other fibrous complications [60], and
should not be used in AADCD. Ergot-derived dopamine
agonists without 5HT2b agonist action (bromocriptine)
have a lower risk, although incidentally, pulmonary,
retroperitoneal and (peri)cardial fibrosis have been de-
scribed, with a dose-effect relation [61]. Non-ergot de-
rived dopamine agonists are pramipexole, ropinirole,
rotigotine (transdermal patches) and apomorphine (sub-
cutaneous). The risk of fibrotic complications with non-
ergot derived dopamine agonists is probably very low
[62].
Use of dopamine agonists in AADCD was described in
58 individual cases, with bromocriptine being used most
often (26 patients), followed by pergolide (11 patients).
Reports on non-ergot derived dopamine agonists were
fewer (4 patients on pramipexole, 4 on rotigotine, and 2
on ropinirole). One patient on cabergoline was de-
scribed. In 9 patients the dopamine agonist was not spe-
cified. There are no reports of the use of subcutaneous
apomorphine in AADCD. Positive responses (e.g. im-
provement of head control, hypotonia, oculogyric crises,
voluntary movements and autonomic symptoms) have
been reported for bromocriptine, pramipexole, rotigotine
patches and pergolide. Also, neutral effects were re-
ported. Reported side effects included irritability, weight
loss, worsening of failure to thrive, vomiting, and also
mild to severe dyskinesia [45]. Overall, benefits out-
weighed side effects in most cases. It is important to
consider that many patients were treated simultaneously
with more than one drug class, therefore assessment of
the impact of a single drug is often problematic. For
dose recommendations of dopamine agonists, see
Table 4.
R#26 (strong): Dopamine agonists should be tried in
the treatment of AADCD. Non-ergot derived dopamine
agonists (pramipexole, ropinirole, rotigotine) are
preferred.
R#27 (strong): Cabergoline and pergolide should not
be used for the treatment of AADCD because of the
high risk of fibrotic complications.
R#28 (GPP): Cardiac screening (see R#48) before and
during treatment with bromocriptine (ergot derived
dopamine-agonists) is indicated, because of the potential
risk of cardiac fibrosis.
MAO inhibitors
MAO inhibitors prevent breakdown of dopamine
and serotonin, thereby increasing monoamine avail-
ability. The effect of MAO inhibitors in AADCD was
described for 31 cases in 17 studies. All patients had
co-treatment with dopamine agonists and/ or pyri-
doxine. MAO inhibitors used were tranylcypromine
(n = 14), selegiline (n = 7), phenelzine (n = 1), or un-
specified (n = 9). No studies were found on rasagi-
line. The majority of studies described an
improvement in at least one clinical endpoint (e.g.
hypotonia), with no effects on others. Some studies
reported no clinical improvement at all, e.g. Anselm
et al [39], or only temporary improvement [40]. Side
effects were rarely reported, apart from one patient
who developed a dystonic crisis on withdrawal of
tranylcypromine [45], and one patient with increased
oculogyric crises [40]. For dose recommendations,
see Table 4.
R#29 (strong): From the biochemical viewpoint there
is strong recommendation for giving patients with
AADCD a trial of MAO inhibitors, although there is lit-
tle evidence of clinical benefit.
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Pyridoxine / pyridoxal phosphate (PLP)
Pyridoxal phosphate (PLP), the active form of pyridox-
ine, is a cofactor of AADC (Fig. 1). Therefore, treatment
with one of several available forms of vitamin B6 might
increase residual activity of the AADC enzyme. Pyridox-
ine is more readily available and cheaper than PLP,
therefore it is the form used most often in AADCD. It
has been reported in about 50 individual patients. The
use of PLP was described in only one study [22]. Pyri-
doxine monotherapy was reported in only 8 patients, of
which only one patient (with a mild phenotype) showed
a clear favorable response [18]. In patients with concur-
rent medications, a favorable effect was sometimes seen.
In 19 patients, no clear response was described at all.
Reported side effects were gastrointestinal complaints,
sleeping problems and extreme motor restlessness in pa-
tients with very high doses of pyridoxine and concurrent
treatment with L-Dopa. Pyridoxine and PLP can cause
reversible polyneuropathy when used in high doses for
long periods of time. For dose recommendations, see
Table 4.
R#30 (strong): Vitamin B6 is considered a first line
treatment from a biochemical standpoint, but dose limits
should be respected because of possible side effects.
R#31 (conditional): Pyridoxine is preferred over PLP
because of availability and costs. If it is not tolerated,
PLP can be tried instead.
Additional symptomatic treatment
Anticholinergic drugs
Anticholinergic drugs (e.g. trihexyphenidyl, benztro-
pine, biperiden) are commonly used to treat certain
movement disorders, especially parkinsonism [63]
and dystonia [64]. Although their exact mechanism
of action is not known, it is thought that they influ-
ence the relative imbalance between dopaminergic
and cholinergic pathways. In AADCD, they can be
used to treat autonomic symptoms, dystonia, and
oculogyric crisis. The effect of anticholinergic medi-
cation is described in only 11 patients, who all re-
ceived concurrent medications (dopamine agonist
and/ or L-Dopa and/ or pyridoxine and/ or MAO-
inhibitors). In the majority of cases there was an im-
provement of at least one clinical endpoint (e.g.
hypotonia, excessive sweating, dystonia). Not all pa-
tients were reported to benefit, however. Side effects
were reported in two articles, including significant
sedation in one patient [39] and aggressive behavior
in another [41]. For dose recommendations, see
Table 4.
R#32 (conditional): Anticholinergic agents can be
considered in AADCD, especially (additionally) to treat
autonomic symptoms, dystonia, and oculogyric crisis.
Melatonin
There is very limited evidence for the use of melatonin
in AADCD. It was reported in only 6 cases. An improve-
ment in sleep pattern was described in 2 cases [41, 45],
1 patient showed no effect [21], and in 3 cases the clin-
ical effect was not described [45]. No side effects have
been reported although some members of the guideline
working group reported experience with patients who
had transient night terrors (unpublished observation).
From a pathophysiological perspective, supplementation
for disorders of sleep induction is reasonable because
melatonin is formed from serotonin and therefore may
be decreased in AADCD. Many AADCD patients suffer
from sleeping disorders, and unpublished observations
of the guideline group support the effect of melatonin in
this patient group. For dose recommendations, see
Table 4.
R#33 (conditional): Melatonin should be considered
for the treatment of sleep disturbances in AADCD.
Benzodiazepines
There is very limited evidence for the use of benzodiaze-
pines in AADCD, since it was reported in only 4 patients
[38, 42, 65]. In one patient, there was a slight improve-
ment of dystonia on clobazam [65]. In another patient,
rectal diazepam was effective in the treatment of pro-
longed oculogyric crises [42]. General dose recommen-
dations can be used.
R#34 (conditional): Benzodiazepines, especially when
used intermittently, can be considered in specific set-
tings, e.g. in sustained oculogyric or dystonic crises.
Other symptomatic treatment
Although no reports specifically evaluate the use of
alpha-adrenoreceptor nose drops in AADCD, its value is
evident in clinical practice to treat nasal congestion. To
reduce side effects of long-term application, the lowest
possible dose should be used. Application should be ac-
companied by local care, e.g. with dexpanthenol contain-
ing ointments. During long-term treatment an
intermittent application of a topical steroid (e.g. flutica-
sone; one spray in each nostril per day for 6 weeks; max-
imal twice per year) can restore the nose drops effect
and reduce the necessary dose (expert opinion). Cloni-
dine, an imidazoline and alpha-2 agonist, can be used
for irritability and sleep disturbance [6]. For dose recom-
mendations, see Table 4. Botulinum toxin injections can
be used in the treatment of dystonia. We have limited
clinical experience with its use in AADCD.
Other treatment options
L-Dopa with or without carbidopa
Patients with AADCD already have highly elevated levels
of L-Dopa, therefore treatment with L-Dopa is
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Table 4 Recommended drugs and doses in AADC deficiency
Class Drug Mechanism Dose recommendation Precaution/comments
FIRST LINE
TREATMENT
AGENTS
Vitamin B6 Pyridoxine (vit
B6)
Cofactor, optimizes
residual AADC activity
Start: 100 mg/d in 2 doses
Max 200 mg/d
May be preferred over pyridoxal
5-phosphate because of cost and
availability
Maintain for 1 year, then
discontinue when in stable
circumstances. If no deterioration,
leave discontinued.
Chronic use in high dose can
cause severe sensorimotor
polyneuropathy
Side effects: generally well
tolerated, sometimes nausea,
vomiting.
Pyridoxal 5-
Phosphate
Cofactor, optimizes
residual AADC activity
Start:100 mg/d in 2 doses.
Max 200 mg/d
Consider trial if pyridoxine gives
too many side effects or is not
effective.
Chronic use in high dose can
cause severe sensorimotor
polyneuropathy
Dopamine
agonists
Pramipexole Non-ergot derived D2-
agonist with preference
for D3 receptor subtype.
Start 0.005 – 0.010 mg/kg/d of
BASE in 1-3 divided doses, in-
crease every 3-7* days by
0.005 mg/kg/d, max 0.075 mg/
kg or 3.3 mg/d of BASE
Distinction in salt and base
content.
Take tablets with water, optional
with food
High risk of drug-induced
dyskinesias
Ropinirole Non-ergot derived D2-
agonist with preference
for D3-receptor subtype.
Suggestion: Start 0.25 mg/d
1 daily 2 h before bedtime;
increase every 3-7* days to 0.5-
4.0 mg/d in 3 divided doses,
max 0.3 mg/kg/d or 24 mg/d
Do not use in severe kidney
failure
Take tablets with food
Very limited experience in AADC
deficiency, physician should
extrapolate and titrate carefully.
Probably high risk of drug-
induced dyskinesias as in other
dopamine agonists.
Rotigotine
patch
Non-ergot derived D2
agonist with preference
for D3; also effect on D2,
D1 and D5; and α2B and
5HT1A agonist.
>12 years and >15 kg:
Start 2 mg/d; weekly increase by
2 mg, max 8 mg/d.
No data available for use in
children <12y/ <15 kg.
Do not cut patches.
Drug induced dyskinesias require
a lower dose and/ or slower
increase
Skin reactions occur often (about
30 %).
Sulphite can lead to allergic
reactions
Remove patch during MRI/
electrocardioversion (aluminium
content)
Bromocriptine Ergot-derived D2-agonist
with D1 receptor antag-
onist effect
Start 0.1 mg/kg/d (max 1.25 mg/
d); increase weekly by 0.1 mg/
kg/d (max 1.25 mg/d) up to
0.5 mg/kg/d (max 30 mg/d) in
2-3 divided doses.
Non-ergot derived dopamine
agonists are preferred
Take tablets with food
Small risk of fibrotic
complications, consider cardiac
screening before and during use.
Higher risk with higher dose,
dose restricted to 30 mg/d in
adults. Maintain lowest effective
dose.
Pergolide or
cabergoline
Ergot-derived None Do not use because of higher risk
of fibrotic complications
MAO-inhibitors Selegiline MAO-B inhibitor (non-
selective in very high
doses)
Start 0.1 mg/kg/d in 2-3 divided
doses. Increase every 2 weeks by
0.1 mg/kg/d up to 0.3 mg/kg/d
or 10 mg/d
Dose at breakfast and lunch,
avoid night-time doses if insom-
nia is experienced.
Dose sublingual preparations
much lower
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counterintuitive, and only reported in 10 cases. However,
in 4 patients with variants at the L-Dopa binding site, a
sustained effect of L-Dopa was seen (see part I). Re-
ported side effects (diarrhea and restlessness) in these
patients were minimal and dose-dependent [19]. No im-
provement was reported in 3 cases [40, 42], and in 3
cases response was not described [2]. The use of carbi-
dopa, an AADC inhibitor, is potentially dangerous in
AADCD from a pathophysiological point of view be-
cause it further inhibits an already deficient enzyme. For
dose recommendations of L-Dopa, see Table 4. In pa-
tients on L-Dopa therapy, extra attention should be
Table 4 Recommended drugs and doses in AADC deficiency (Continued)
Tranylcypromine Non-selective MAO-A
and -B inhibitor
Start 0.1 mg/kg/d in 2 doses.
Increase every 2 weeks by
0.1 mg/kg/d up to 0.5 mg/kg/d
(max 30 mg)
Dose at breakfast and lunch,
avoid night-time doses if insom-
nia is experienced.
Occurrence of ‘cheese effect’
(hypertensive crises when foods
with high content of tyramine
are ingested) is very unlikely in
patients with AADC deficiency
due to their low levels of
dopamine, norepinephrine and
epinephrine.
ADDITIONAL
SYMPTOMATIC
TREATMENT
Anticholinergics
(dystonia/
autonomic
symptoms)
Trihexyphenidyl Anticholinergic agents,
restores neurotransmitter
disbalance
<15 kg: start 0.5-1 mg/d in 1
dose; increase every 3-7* days
by 1 mg/d in 2-4 doses/d
>15 kg: start 2 mg/d in 2 doses;
increase every 3-7* days by2mg/
d in 2-4 divided doses.
Effective dose highly variable (6-
60 mg)
Maximum dose: <10 kg 30 mg/
d; >10 kg 60 mg/d
In general, the younger, the
better tolerated; dosages often
exceed recommended dose for
adults (15 mg/d).
Maximum dose is dictated by
side effects: e.g. dry mouth, dry
eyes, blurred vision (mydriasis),
urine retention, constipation.
Sedation in high doses.
Benztropine Centrally acting
anticholinergic agent.
Also dopaminergic effect
by inhibiting presynaptic
reuptake
Start 1 mg in 2 divided doses,
increase weekly up to 4 mg/d
Anticholinergic side effects: e.g.
dry mouth, dry eyes, blurred
vision (mydriasis), urine retention,
obstipation. Sedation in high
doses.
Nasal
congestion
Oxymetazoline
or
xylometazoline
nosedrops
α-adrenergic agonist
leading to local
vasoconstriction
Use general dose guidelines for
age, try to use lowest available
dose in chronic use
Try to include intermittent weeks
without treatment to prevent
habituation
Hypertensive crises if used
concomitantly with MAO-
inhibitors is very unlikely in pa-
tients with AADC deficiency due
to their levels of dopamine, nor-
epinephrine and epinephrine
Sleeping
problems
Melatonin Regulates onset of sleep
and day/night cycling
Start 3 mg/d, given 4 h before
onset of sleep. Max dose 5-
8 mg/d
Transient night terrors on initial
treatment can occur (personal
experience)
Availability differs between
countries.
Irritability/ sleep
disturbance
Clonidine Centrally acting
antihypertensive drug;
imidazoline (I1-) and α2-
agonist
Start 0.1 mg/d ante noctum,
increase to max 3 mg/d ante
noctum
Monitor blood pressure in higher
dose
Sedative, therefore give AN
SPECIAL CASES
ONLY
L-Dopa binding
site variant
L-Dopa without
carbidopa
Substrate for AADC to
form dopamine; effective
in certain binding site
variants
Start 0.5-1 mg/kg/d in 3 divided
doses, increase 2 weekly by
1 mg/kg to 5 mg/kg/d. Only if
clinical effective, further increase
to max 15 mg/kg/d
Start as first line treatment only if
known binding site variant.
Otherwise, consider as third-line
treatment trial for 2 months (or
less if deterioration) when in
stable clinical situation.
Monitor CSF during treatment,
including 5-MTHF
Low 5-MTHF in
CSF
Folinic acid
(calcium
folinate)
Methylation of excessive
amounts of L-Dopa in
AADCD may cause deple-
tion of methyl donors.
1-2 mg/kg/d, max 20 mg/ d Only supply if 5-MTHF is low in
CSF
Monitor 5-MTHF in CSF during
treatment with L-Dopa
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given to folinic acid supplementation because of possible
depletion.
R#35 (strong): L-Dopa is first line treatment only for
patients with L-Dopa binding-site variants (e.g.
p.[G102S], p.[R347Q], p.[R160W]). On theoretical
grounds, L-Dopa without carbidopa is preferred.
R#36 (conditional): In patients without proven L-
Dopa binding-site variants,, an L-Dopa trial can be con-
sidered if other treatment options fail.
R#37 (strong): CSF 5-MTHF levels should be deter-
mined before and during L-Dopa therapy.
Folinic acid
In theory, secondary cerebral folate deficiency may de-
velop in AADCD since O-methylation of the excessive
amounts of L-Dopa to 3-OMD depletes methyl donors
including SAM and 5-MTHF. However, decreased levels
of CSF 5-MTHF were only reported in a very limited
number of patients (see part IIa). The therapeutic use of
folinic acid in AADCD is reported in 4 patients [21, 22,
47]. In three patients, some improvement was seen. No
side effects were published, but several members of the
guideline working group reported gastro-intestinal side
effects in AADCD patients (unpublished observations).
Costs and insurance covering of folinic acid varies
amongst countries. Low CSF 5-MTHF levels must be
supplemented with folinic acid, not folic acid. Dose rec-
ommendations can be found in Table 4.
R#38 (conditional): Supplementation with folinic acid
can be considered in all patients, and is clearly recom-
mended when 5-MTHF in CSF is low.
R#39 (research): Further research on 5-MTHF is
needed to be able to give strong recommendations on
folinic acid supplementation and 5-MTHF follow-up in
AADCD. At this moment, we do not recommend regu-
lar follow-up lumbar punctures in stable patients. In
case of unexpected clinical deterioration, measurements
of CSF 5-MTHF should be considered to rule out sec-
ondary folate deficiency.
5-Hydroxytryptophan
5-HTP is the substrate for AADC to form serotonin,
and its use in AADCD is as counterintuitive as the use
of L-Dopa. Use of 5-HTP in AADCD was described in 5
patients [34, 40, 47, 56]. None showed a positive effect.
In contrast, 2 patients showed side effects: lethargy, in-
creased axial hypotonia, and abdominal pain.
R#40 (strong): Based on the current evidence and
pathophysiological mechanisms, 5-HTP should not be
used in the treatment of AADCD.
Selective serotonin reuptake inhibitors (SSRIs)
The use of SSRIs (paroxetine, ergotamine and fluoxet-
ine) was reported in 4 patients with AADCD [5, 40, 45,
56]. Only one patient showed a possible, unspecified re-
sponse. The other 3 patients showed no clinical benefit,
but experienced side effects including worsening of ocu-
logyric crises and hypotonia, lethargy, and dystonic
reactions.
R#41 (conditional): Based on the current evidence,
the use of SSRIs in AADCD is not recommended.
Treatment schedule AADCD
In Table 4, recommended drugs and doses are summa-
rized. Figure 2 shows a schematic example of how a pa-
tient with newly diagnosed AADCD can be treated. In
recommendation 42 the most important treatment prin-
ciples of AADCD are given:
R#42 (strong): The core recommendations for med-
ical treatment of AADCD are:
1) First line treatment agents are selective dopamine
agonists, MAO-inhibitors, and pyridoxine
2) Additional symptomatic treatment agents are
anticholinergic agents, melatonin, benzodiazepines,
and alpha-adrenoreceptor blockers.
3) In general, therapy with multiple drugs will be
needed and doses should be titrated individually and
sequentially.
4) General treatment principles to adhere to are: step-
wise approach, start low and go slow when increas-
ing the doses, and discontinue/ wean off medication
that is not helpful.
R#43 (research): Since the evidence for medical treat-
ment in AADCD is low to very low, it would be desir-
able to conduct randomized clinical trials in AADCD to
improve the proposed treatment schedule.
Drugs to avoid in AADCD
Centrally acting dopamine antagonists, used for their an-
tiemetic and antipsychotic properties, should be avoided
in AADCD because they have the potential to worsen
symptoms of dopamine deficiency. The detrimental ef-
fects of haloperidol (antagonist at dopamine 2 receptors)
are illustrated in one case report [39]. Metoclopramide
should not be used for the treatment of nausea. Levome-
promazine, an agent with antagonistic properties to epi-
nephrine, histamine, acetylcholine, dopamine, and
serotonin, led to severe side effects in one patient [46].
Less is known about serotonin antagonists like 5-HT3
receptor blockers that are used as antiemetics (e.g.
ondansetron, granisetron). From a pathophysiological
standpoint, side effects can be expected and their use
should be avoided, but there is no literature or clinical
experience available. It is important to realize that many
drugs have antagonistic properties for several neuro-
transmitters, and before introducing any drug to
Wassenberg et al. Orphanet Journal of Rare Diseases  (2017) 12:12 Page 14 of 21
AADCD patients, its potential benefits and harms
should be considered carefully.
In case of nausea and vomiting in AADCD pa-
tients, supportive care to avoid dehydration and
hypoglycemia is most important. If possible, anti-
dopaminergic and anti-serotonergic agents should be
avoided. If medical therapy is needed, low dose dom-
peridone can be considered. Local guidelines on
availability, cardiac concerns and dose recommenda-
tions should be followed. Although domperidone is a
dopamine antagonist, it does not cross the blood
brain barrier and therefore side-effects in AADCD
are expected to be limited.
R#44 (strong): Centrally acting dopamine antagonists
should be avoided in AADCD.
R#45 (GPP): Supportive care in nausea and vomiting in
AADCD patients should be optimal. If medical treatment
is needed, low-dose domperidone can be considered.
Dystonic crisis (status dystonicus)
Dystonic crisis can occur in AADCD patients, but lim-
ited data is available about the prevalence of and
Fig. 2 Treatment algorithm in AADC deficiency. This figure reflects a possible treatment scheme for a newly diagnosed AADCD patient. Drug
dose and escalating schemes are given in Table 4. At the left, first line treatment is depicted in which pyridoxine is started at diagnosis (step (1)),
followed after two weeks by step (2): either one of the dopamine agonists in escalating scheme or one of the MAO-inhibitors. After two months
of treatment at target dose, step (3) is added: either a dopamine agonist or a MAO-inhibitor. The order of introducing dopamine agonist or
MAO-inhibitors is interchangeably. Dose escalation depends on effect and tolerability. If an agent is not effective or has too many side effects,
consider replacing it with another agent from the same class before going to the next step. In case of intolerable side effects, treatment should
be stopped. After about 1 year in stable treatment regimen, reassessment should take place: consider to discontinue drugs (only 1 at a time)
without clear treatment effect. Frequent assessment is then again necessary, and agents should be reinstated in case of deterioration. At the right,
additional symptomatic treatment is depicted, with different drug classes that could be added for specific symptoms. Always avoid starting more
than 1 agent at the time. Assess tolerability and effect frequently, and discontinue drugs that have no clear effect, or give intolerable side effects.
Treatment in special situations (L-Dopa, folinic acid) is not depicted in this figure (see text). Abbreviations: DA-agonist: dopamine agonist; MAOI:
MAO-inhibitor; OGC: oculogyric crisis
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treatment approach to this rare, potentially life-
threatening complication. A dystonic crisis is often trig-
gered by infection or medication adjustments. It is char-
acterized by sustained severe dystonic muscle
contractions that can lead to airway compromise and
metabolic complications such as rhabdomyolysis leading
to acute renal failure [66]. The approach to dystonic cri-
sis in AADCD should be similar to the general ap-
proach, with admission to an intensive care unit, fluid
and nutrition supplementation, sedation (usually with
benzodiazepines) and respiratory support if needed.
Dopamine antagonists and L-Dopa should not be used
in AADCD. For a review, see [67].
R#46 (GPP): Dystonic crisis in AADCD is a poten-
tially life-threatening condition and should be treated
promptly.
IIIb: Non-medical treatment
Paramedical treatment in AADCD
Although there are no studies or reports on the effects
of paramedical treatment in AADCD, a multidisciplinary
approach with physiotherapy, speech therapy, occupa-
tional therapy, feeding and nutritional assessment, and
(neuro)psychological treatment and support is essential
to prevent secondary complications and promote devel-
opment. A physiatrist (rehabilitation specialist) is also a
valuable member of the team. In this respect, approach
to a patient with AADCD is comparable to the approach
of other chronic neurological disorders, e.g. cerebral
palsy.
R#47 (GPP): Involvement of a multidisciplinary team
that includes a rehabilitation physician (physiatrist) and
allied health professionals (paramedical therapy services)
is essential in the care for AADCD patients.
Gene therapy and other surgical treatment options
Gene therapy in which a viral vector (adeno-associated
virus type 2) encoding cDNA of the human DDC gene is
delivered to targeted brain structures was originally de-
veloped for patients with Parkinson’s disease [68]. Gene
transfer to the bilateral putamen has been performed in
four AADCD patients in Taiwan with modest but prom-
ising results [24]. Further research is ongoing. Clinical
trials are presently recruiting patients in Taiwan and
Japan [11, 12], and trials in the USA and Europe, in
which gene transfer will target midbrain structures, are
anticipated [69]. There is no experience with deep brain
stimulation or other surgical treatment options in
AADCD.
R#48 (research): Gene therapy for AADCD is cur-
rently under development in research setting. Clinical
trial results will determine whether further implementa-
tion of this promising therapy may occur in the future.
Part IV: Complications and long-term manage-
ment in AADCD
Cardiac decompensation
Structural cardiac abnormalities in AADCD are not ex-
pected from a pathophysiological perspective. In one
case report, electrocardiogram and heart ultrasound
were reported as normal [34], but in most reports infor-
mation regarding cardiac status is lacking. There are in-
dividual descriptions of one patient with bradycardia on
ECG [20], and one patient who suffered from a wit-
nessed cardiac arrest at age 9 years, with ensuing per-
manent neurological damage [59]. It is possible that
cathecholaminergic deficiency and autonomic dysfunc-
tion may potentially lead to cardiac complications, which
may be more evident during illness or stress (e.g. inter-
current infections, surgical interventions).
R#49 (strong): There should be awareness for possible
cardiac complications in AADCD patients during poten-
tially stressful situations and cardiac monitoring during
these instances is recommended. Regular follow-up car-
diac screening is not needed, but recommended before
any anesthesia or intervention. If available in local care
setting, cardiac screening should consist of a referral to
a (pediatric) cardiologist for clinical evaluation, ECG and
echocardiogram. For cardiac screening for patients on
dopamine agonists, see recommendation #28.
Orthopaedic complications
Orthopaedic complications are reported in AADCD sec-
ondary to severe motor impairment (abnormalities of
tone, posture, paucity of movement). Contractures lead-
ing to mobilization problems are described in a few pa-
tients [7, 39]. A multidisciplinary approach for follow-up
and treatment is recommended. Orthopaedic monitoring
(e.g. hip and spine X-rays) is recommended, preferably
in a local care setting.
R#50 (GPP): AADCD patients should be monitored
for orthopaedic complications following standards of
good care for patients with motor impairment.
Infections
There is an increased risk of infections in AADCD pa-
tients, likely not because of disease-specific mechanisms
but secondary to complications including impaired feed-
ing and swallowing, reduced mobility, and recurrent
hospitalization. A disease specific aspect of AADCD
could be the reduced response to stress of infections,
which can be fatal. Treating physicians (specialists and
primary care physicians) should be aware of this. Fur-
thermore, hyperthermia in AADCD can be due to auto-
nomic temperature dysregulation and may not always
represent a fever due to underlying infection. Vaccina-
tions following local vaccination programs are
recommended.
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R #51 (GPP): Because AADCD patients have a re-
duced response to stress, close monitoring during infec-
tions is recommended.
R#52 (GPP): Vaccinations following local vaccination
programs are recommended in AADCD.
Follow-up visits
R#53 (strong): AADCD patients should be seen at least
yearly by a (child) neurologist with experience in move-
ment disorders or neurometabolic disease, ideally in a
multidisciplinary setting (see R#46), facilitating a shared-
care approach.
Emergency card
R#54 (GPP): It is recommended that all AADCD pa-
tients receive an emergency card including short infor-
mation on AADCD, possible complications, and drugs
to avoid in this disorder. An agreed emergency card can
be found as Additional file 3.
Part V: Social issues and transition
Psychological support for families
There are no reports on the health and well-being of
caregivers of children with AADCD available. However,
studies in families with children with chronic diseases
show that caregivers are at risk of reduced quality of life.
Family stress and parental coping are factors that are as-
sociated with quality of life [70]. For more background
information and strategies to improve support for par-
ents of chronically ill children, see e.g. Newton and
Lemarche [71]. Quality of life assessment and the evalu-
ation of disease burden in family members of AADCD
patients are an essential part of the ongoing iNTD regis-
try study [9].
In isolated case reports, an increased prevalence of
psychiatric disorders in carriers of AADCD has been de-
scribed. To date, this has neither been systematically
evaluated nor consistently reported [35, 45].
R#55 (strong): If available in local care setting, psy-
chological support (e.g. psychologist, social worker) to
caregivers, siblings, and patients with AADCD is
recommended
R#56 (research): Further research is needed to clarify
whether DDC gene variant carriers have a primary (gen-
etically determined) increased risk of psychiatric
symptoms.
Genetic counseling
Although there is no specific literature on genetic
counseling in AADCD available, it can be considered
good clinical practice for all parents of children with
AADCD to be offered standard genetic counseling,
considering the autosomal recessive nature of the dis-
order. See also R#60.
R#57 (strong): If available in local care settings, all
parents of patients with AADCD should be offered
standard genetic counseling.
Parental organizations
There are two internationally operating non-profit par-
ental organizations for patients with AADCD: the UK
based AADC Research Trust (www.aadcresearch.org)
and the USA based Pediatric Neurotransmitter Disease
Association (www.pndassoc.org). Furthermore, there is
the Spanish neurotransmitter diseases association “De
neu” (www.deneu.org). The major aim of these organiza-
tions is to help and support patients with AADCD by
providing information and organizing family meetings,
promoting disease awareness and funding scientific
research.
R#58 (strong): It is recommended that caregivers of
AADC deficient patients be informed about existing par-
ental organizations for this rare disorder.
Transition from child to adulthood
No specific reports are available on the healthcare tran-
sition of patients with AADCD from childhood to ado-
lescence to adulthood. Most reports focus on patients in
infancy and childhood. There is no information pub-
lished on puberty. Also fertility concerns or pregnancy
has not been described in AADCD. Considering the
often severe phenotype, for the majority of patients this
will not be an issue. However, relatively mildly affected
patients have been described [35] and the phenotypic
spectrum continues to expand. Based on experience with
other disorders that cause neurodevelopmental disability,
it is known that there are significant gaps in our know-
ledge and practice about healthcare transition for young
adults [72]. The transfer from intense, family-oriented
pediatric care, to primarily individually focused adult
care is often perceived as difficult for both patients and
caregivers [73]. Local differences in health care
organization for patients with neurodevelopmental dis-
abilities will be present across countries. Based on the
literature, it is not possible to give specific recommenda-
tions on transition of care for patients with AADCD.
However, the guideline committee clearly states that this
process should be adequately prepared. Continuation of
the multidisciplinary care setting is recommended.
R#59 (GPP): Transition of AADCD patients to adult
care should be prepared well, and continue to take place
in specialized centers. Multidisciplinary care should be
continued.
R#60 (research): Follow-up studies of adult patients
with AADCD are strongly recommended to better de-
fine prognosis and possible new clinical symptoms and
signs in adolescence and adulthood.
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Part VI: Special situations
Anesthesia for interventions
It is not unusual for patients with AADCD to need
anesthesia for (minor) interventions such as gastros-
tomy. Only two reports described anesthesia manage-
ment in two different AADCD patients [29, 30]. It
should be noted that intravenous phenylephrine and
dopamine may lead to an exaggerated hemodynamic re-
sponse in these patients. In case of hypotension during
intervention, dopamine should be initiated at low dose
(e.g. 1-2 ug/kg/min) [29]. Monitoring of hemodynamic
function, temperature and glucose levels is important,
especially in prolonged interventions.
R#61 (strong): Anesthesia should be well prepared in
patients with AADCD because patients have an in-
creased risk of hemodynamic instability and
hypoglycemia. In addition to cardiovascular monitoring,
monitoring of temperature and glucose levels during
procedures is recommended. In general, it is recom-
mended to continue standard treatment (including
MAO inhibitors) during interventions.
Intensive Care management
Information on ICU management of AADC deficient pa-
tients is limited. In a case report of one patient, cardiac
complications are described during ICU treatment with
exogenous catecholamines [39]. Another case report de-
scribed one patient with a 5-h period of hypotension
with bradycardia following sedation at age 11 years [59].
Autonomic testing in two patients showed severe im-
pairment of sympathetic blood pressure modulation in
both. In the more severely affected patient, recurrent ep-
isodes of cardiorespiratory arrest, preceded by profound
bradycardia, were described, evoked by painful stimuli
(e.g. blood draw) [45].
R#62 (strong): AADCD leads to sympathetic impair-
ment with possible cardiac complications. This should
be anticipated during ICU admissions.
Prenatal diagnosis
Prenatal diagnosis of AADCD might be possible by
measuring 3-OMD, 5-HTP and L-Dopa in amniotic fluid
or fetal plasma [74], but if both disease-causing genetic
variants are known, the most reliable method of prenatal
diagnosis is to perform genetic analysis of chorionic villi
or amniotic fluid cells.
In two reports, successful pre-implantation genetic
diagnosis has been described. In four of five families,
unaffected live births were achieved [75]. In a report
from the same group, Chen et al describe this tech-
nique in a diverse group of single gene disorders in-
cluding AADCD [76].
R#63 (strong): If local resources allow, prenatal gen-
etic diagnosis or preimplantation techniques should be
offered to carriers of AADCD.
Conclusions
AADCD is an early onset disorder with a combined defi-
ciency of serotonin, dopamine, norepinephrine and epi-
nephrine. Key clinical symptoms are hypotonia,
movement disorders (especially oculogyric crisis, dys-
tonia and hypokinesia), developmental delay, and auto-
nomic symptoms. The phenotypic spectrum is broad
and can range from very severe to relatively mild. There
are no clear genotype/ phenotype correlations in
AADCD except for the homozygous IVS6 + 4A > T splice
variant that is associated with a severe phenotype in all
cases reported to date, and has an increased incidence in
people of Chinese ethnicity.
There are three core diagnostic tools for identifying
AADCD:
1) Low CSF levels of 5-HIAA, HVA and MHPG, with
normal CSF pterins, and increased CSF levels of L-
Dopa, 3-OMD and 5-HTP
2) Genetic diagnosis showing compoung heterozygous
or homozygous disease causing variants in the DDC
gene
3) Decreased AADC enzyme activity in plasma
To diagnose AADCD, genetic testing should be per-
formed and at least two out of three core diagnostic
tests should be positive. If local resources allow, we rec-
ommend performing all three key diagnostic tests in pa-
tients with this rare disorder.
The core recommendations for treatment of AADCD
are:
1) First line treatment with selective dopamine
agonists, MAO-inhibitors, and pyridoxine;
2) Additional symptomatic treatment agents with
anticholinergic agents, melatonin, benzodiazepines,
and alpha-adrenoreceptor blockers
3) In general, multiple drug classes will be needed
4) Overall treatment principles to adhere to are: step-
wise approach, start low and go slow when increas-
ing dosages, and discontinue/ gradually withdraw
medication that is not helpful.
Involvement of a multidisciplinary team, including
physiatrist and paramedical therapy services, is essential
in the care for AADCD patients, and psychological sup-
port should be offered to caregivers, siblings and pa-
tients. Patients and caregivers should be informed about
the AADCD parental organizations. AADCD patients
should be seen at least yearly by a (child) neurologist
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with experience in movement disorders or neurometa-
bolic disease, ideally in a multidisciplinary setting, facili-
tating a shared-care approach.
Although the level of evidence mainly consisted of
level 3 and 4 (non-analytical studies and expert opinion),
using SIGN and GRADE methodology permitted us to
form the strong and conditional recommendations pro-
vided in this guideline. We believe that this consensus
guideline will improve the care of AADCD patients
around the world. Furthermore, we determined several
knowledge voids that should be addressed in future
research.
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